Page last updated: 2024-09-04

tipifarnib and Graft vs Host Disease

tipifarnib has been researched along with Graft vs Host Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dürr, C; Finke, J; Fisch, P; Gerlach, U; Hechinger, AK; Hofmann, M; Leonhardt, F; Maas, K; Marks, R; Pircher, H; Prinz, G; Zeiser, R	1

Other Studies

1 other study(ies) available for tipifarnib and Graft vs Host Disease

Article	Year
Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells. Haematologica, 2013, Volume: 98, Issue:1 Topics: Animals; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; Graft vs Host Disease; Graft vs Leukemia Effect; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Prenylation; Protein Prenylation; Quinolones; Treatment Outcome	2013

Article

Year

Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells.

Haematologica, 2013, Volume: 98, Issue:1

Topics: Animals; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; Graft vs Host Disease; Graft vs Leukemia Effect; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Prenylation; Protein Prenylation; Quinolones; Treatment Outcome

2013